Compare ERII & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | MYGN |
|---|---|---|
| Founded | 1992 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.7M | 372.1M |
| IPO Year | 2008 | 1996 |
| Metric | ERII | MYGN |
|---|---|---|
| Price | $6.72 | $5.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $8.00 | $4.11 |
| AVG Volume (30 Days) | 713.8K | ★ 2.7M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $134,987,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $44.10 | $5.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $6.56 | $2.74 |
| 52 Week High | $18.30 | $8.50 |
| Indicator | ERII | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 74.13 |
| Support Level | N/A | $5.57 |
| Resistance Level | $7.15 | $6.34 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 19.33 | 92.25 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.